KYMR
Kymera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$117.75
−0.62%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$1.25
- Revenue estimate
- $3.3M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.62
- EPS estimate
- -$0.71
- Revenue actual
- $65.0M
- Revenue estimate
- $32.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -6.9%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $139
- PT range
- $115 – $170
- Analysts
- 12
10 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.71 | -$0.62 | Beat 12.99% | $65.0M |
| Apr 30, 2026 | -$0.89 | -$0.71 | Beat 20.22% | $34.4M |
| Feb 26, 2026 | -$0.77 | -$1.03 | Miss -33.93% | $2.9M |
| Nov 4, 2025 | -$0.71 | -$0.90 | Miss -26.76% | $2.8M |
| May 9, 2025 | -$0.92 | -$0.82 | Beat 10.87% | $22.1M |
| Feb 27, 2025 | -$0.76 | -$0.88 | Miss -15.79% | $7.4M |
| Oct 31, 2024 | -$0.83 | -$0.82 | Beat 1.20% | $3.7M |
| May 2, 2024 | -$0.73 | -$0.69 | Beat 5.48% | $10.3M |
| Feb 22, 2024 | -$0.44 | -$0.25 | Beat 43.18% | $47.9M |
| Nov 2, 2023 | -$0.73 | -$0.90 | Miss -23.29% | $4.7M |
| Aug 3, 2023 | -$0.70 | -$0.67 | Beat 4.29% | $16.5M |
| May 4, 2023 | -$0.69 | -$0.70 | Miss -1.45% | $9.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026